Cited 0 time in
Characteristics of Drug Resistance Mutations in a Korean HIV/AIDS Cohort, and Risk Factors for Resistance Acquisition in ART-Experienced Patients
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lee, Minkyeong | - |
| dc.contributor.author | Kim, Soo Min | - |
| dc.contributor.author | Kim, Jun Hyoung | - |
| dc.contributor.author | Park, Bo Young | - |
| dc.contributor.author | Choi, Jun Yong | - |
| dc.contributor.author | Kim, Jung Ho | - |
| dc.contributor.author | Kim, Young Keun | - |
| dc.contributor.author | Kim, Sang Il | - |
| dc.contributor.author | Kim, Shin-Woo | - |
| dc.contributor.author | Hur, Jian | - |
| dc.contributor.author | Kim, Yeonjae | - |
| dc.contributor.author | Choi, Hee Jung | - |
| dc.contributor.author | Song, Joon Young | - |
| dc.contributor.author | Jeong, Oeuk | - |
| dc.contributor.author | Go, Min Jin | - |
| dc.contributor.author | Ryou, Sangmi | - |
| dc.contributor.author | Kim, Hee-Sung | - |
| dc.contributor.author | Jeong, Hye Won | - |
| dc.date.accessioned | 2026-05-09T05:01:33Z | - |
| dc.date.available | 2026-05-09T05:01:33Z | - |
| dc.date.issued | 2026-03 | - |
| dc.identifier.issn | 2093-2340 | - |
| dc.identifier.issn | 2092-6448 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/212527 | - |
| dc.description.abstract | We aimed to characterize human immunodeficiency virus (HIV) drug-resistance mutations among patients in Korea HIV/acquired immunodeficiency syndrome (AIDS) Cohort. Among 1,579 surveyed between December 2006 and December 2020, 148 had resistance mutations (64 ART-naïve and 84 ART-experienced). The most common mutations in ART-naïve patients were related to non-nucleoside reverse transcriptase inhibitors (V179F/D/E/L; 50.0%), whereas those in ART-experienced were M184V/I (73.8%), conferring resistance to nucleotide reverse transcriptase inhibitors. Multivariate logistic regression identified poor compliance (adjusted odds ratio [aOR], 18.780; 95% confidence interval [CI], 1.883–187.300; P=0.012) and viral load ≥1-100,000 copies/mL at ART initiation (aOR, 3.117; 95% CI, 1.160–8.374; P=0.024) as being associated with resistance mutations. | - |
| dc.format.extent | 7 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 대한감염학회 | - |
| dc.title | Characteristics of Drug Resistance Mutations in a Korean HIV/AIDS Cohort, and Risk Factors for Resistance Acquisition in ART-Experienced Patients | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.3947/ic.2025.0120 | - |
| dc.identifier.scopusid | 2-s2.0-105036100402 | - |
| dc.identifier.wosid | 001733241800012 | - |
| dc.identifier.bibliographicCitation | Infection and Chemotherapy, v.58, no.1, pp 105 - 111 | - |
| dc.citation.title | Infection and Chemotherapy | - |
| dc.citation.volume | 58 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 105 | - |
| dc.citation.endPage | 111 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART003323045 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | esci | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Infectious Diseases | - |
| dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
| dc.subject.keywordPlus | ANTIRETROVIRAL THERAPY | - |
| dc.subject.keywordPlus | NAIVE | - |
| dc.subject.keywordAuthor | Drug resistance | - |
| dc.subject.keywordAuthor | HIV/AIDS | - |
| dc.subject.keywordAuthor | Korea | - |
| dc.identifier.url | https://icjournal.org/DOIx.php?id=10.3947/ic.2025.0120 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
